Boston Scientific (NYSE: BSX) EVP reports equity awards and tax share dispositions
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Boston Scientific EVP Arthur C. Butcher reported multiple equity transactions in company stock and units. On February 13, 2026, he acquired 25,380 shares of common stock in two grant or award acquisitions, and also acquired shares through exercises of restricted stock units tied to long‑term incentive programs. He disposed of 25,150 shares of common stock on February 13, 2026 and smaller amounts on later dates to cover tax liabilities at $74.73 per share. Following these moves, he directly held 55,792 shares of common stock and indirectly held 13,354 shares through the company 401(k) plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
7,956 shares exercised/converted
Mixed
12 txns
Insider
Butcher Arthur C
Role
EVP& Grp Pres, MedSurg & APAC
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 2,546 | $0.00 | -- |
| Exercise | Common Stock | 2,546 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,229 | $74.73 | $92K |
| Exercise | Restricted Stock Units | 3,173 | $0.00 | -- |
| Exercise | Common Stock | 3,173 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,535 | $74.73 | $115K |
| Exercise | Restricted Stock Units | 2,237 | $0.00 | -- |
| Grant/Award | Common Stock | 25,380 | $0.00 | -- |
| Grant/Award | Common Stock | 25,380 | $0.00 | -- |
| Exercise | Common Stock | 2,237 | $0.00 | -- |
| Tax Withholding | Common Stock | 25,150 | $74.73 | $1.88M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 57,021 shares (Direct);
Common Stock — 13,354 shares (Indirect, By 401(k))
Footnotes (1)
- On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
